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Abstract
Introduction: Data that provide clinical criteria for the identification of patients likely to respond to high-frequency
oscillatory ventilation (HFOV) are scarce. Our aim was to describe physiological predictors of survival during HFOV
in adults with severe acute respiratory distress syndrome (ARDS) admitted to a respiratory failure center in the
United Kingdom.
Methods: Electronic records of 102 adults treated with HFOV were reviewed retrospectively. We used logistic
regression and receiving-operator characteristics curve to test associations with oxygenation and mortality.
Results: Patients had severe ARDS with a mean (SD) Murray’s score of 2.98 (0.7). Partial pressure of oxygen in
arterial blood to fraction of inspired oxygen (PaO2/FiO2) ratio and oxygenation index improved only in survivors.
The earliest time point at which the two groups differed was at three hours after commencing HFOV. An
improvement of >38% in PaO2/FiO2 occurring at any time within the first 72 hours, was the best predictor of
survival at 30 days (area under the curve (AUC) of 0.83, sensitivity 93%, specificity 78% and a positive likelihood
ratio (LR) of 4.3). These patients also had a 3.5 fold greater reduction in partial pressure of carbon dioxide in arterial
blood (PaCO2). Multivariate analysis showed that HFOV was more effective in younger patients, when instituted
early, and in patients with milder respiratory acidosis.
Conclusions: HFOV is effective in improving oxygenation in adults with ARDS, particularly when instituted early.
Changes in PaO2/FiO2 during the first three hours of HFOV can identify those patients more likely to survive.
Introduction
Patients with acute respiratory distress syndrome
(ARDS) exhibit a highly inhomogeneous, compliance-
dependent distribution of regional ventilation during
conventional mechanical ventilation (CMV) [1]. Conse-
quently, CMV can lead to further lung injury through
tidal hyperinflation and shear stress injury, even when it
is administered according to a ‘lung protective strategy’
that limits tidal volumes and plateau pressure [2], and
employs recruitment maneuvers to maximize the pro-
portion of aerated alveolar tissue [1]. High-frequency
oscillatory ventilation (HFOV) can theoretically offer
effective lung protective ventilation by delivering very
low tidal volumes (1 to 3 mL Kg-1) around a fixed mean
airway pressure at frequencies of 5 to 12 Hz (lower fre-
quencies are used in adults). At high respiratory fre-
quencies, the short inspiratory time results in a
distribution of ventilation which, compared to mechani-
cal ventilation at conventional breathing rates, is more
homogeneous and less dependent on the distribution of
regional lung compliance [3,4]. This results in the pro-
tection of the recruited lung (with greater compliance)
from excessive cyclic variations in alveolar pressure. In
addition, if the continuous distending pressure (CDP) is
optimized following a stepwise recruitment maneuver,
the more compliant lung regions are less susceptible to
static hyperinflation [3,5,6], thereby reducing lung strain
and ventilation-induced inflammation [7,8].
HFOV improves gas exchange and reduces lung injury
in animal models of ARDS [9-11] and in human neona-
tal and pediatric populations [12-15]. In adults the
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effects of HFOV are largely limited to observational stu-
dies [16-24] and two randomized trials [25,26]. Overall
these studies show that HFOV might improve gas
exchange and survival. However, data that provide clini-
cal criteria for identification of patients likely to benefit
from HFOV are scarce [23,24]. Large studies outside
North America, utilizing different protocols are lacking,
although the results of two multicenter clinical trials in
the UK and Canada (OSCAR and OSCILLATE trials)
are awaited [16,27,28].
In this study we aim to describe potential physiologi-
cal predictors of survival during HFOV in adults with
severe ARDS admitted to an advanced respiratory failure
center in the United Kingdom.
Materials and methods
Patients
This was a single center observational study of patients
with ARDS admitted to the Adult Intensive Care Service
at Guy’s and St Thomas’ Hospital in London between
1998 and 2002. We included patients who were treated
with HFOV because of severe gas exchange impairments
while on CMV. Medical records and physiological data
before, during and after HFOV were retrieved from our
ICU electronic patient record (Intellivue Clinical Infor-
mation Portfolio, Philips Medical Systems UK Limited).
Patients’ demographic data, hemodynamic variables,
oxygenation and ventilator settings were recorded while
on CMV prior to HFOV, during HFOV, prior to discon-
tinuation of HFOV and on recommencement of CMV.
Oxygenation index (OI = (FiO2CDP 100)/PaO2) and
partial pressure of oxygen in arterial blood to fraction of
inspired oxygen (PaO2/FiO2) ratio were calculated at the
same intervals. Acute Physiology and Chronic Health
Evaluation (APACHE II) and Murray lung injury sever-
ity score (which combines degree of lung infiltration on
chest × ray, lung compliance, PaO2/FiO2 and positive
end expiratory pressure (PEEP)) [29] at admission and
on commencement of HFOV were determined (with a
blinded and independent radiologist scoring the chest x-
ray appearance). Hemodynamic data were obtained
using cardiac output monitors PiCCOplus (Pulsion,
Munich, Germany, Software version 7.0 non USA), or a
LiDCO (LiDCO Ltd, London, UK). This study was con-
sidered by the National Research Ethics Service as ‘ser-
vice evaluation’ and therefore did not require Research
Ethics Committee review [30].
Ventilator settings and study protocol
All patients were ventilated with pressure-controlled
ventilation before starting HFOV, using a lung protec-
tive strategy [31,32]. Patients were considered for HFOV
if SaO2 <88%/PaO2 <60 mmHg, FiO2 >0.6 and pH <7.2.
HFOV was delivered using an adult high-frequency
oscillatory ventilator (3100B, Viasys (CareFusion), Yorba
Linda, CA, USA). All patients were initiated onto HFOV
using the following settings: a FiO2 of 1.0, a frequency
of 4 to 6 Hz, inspiratory time of 33%, a bias flow of 30
to 40 Lmin-1, a CDP set 3 to 5 cmH2O above the CDP
during CMV and a Power to obtain transmitted oscilla-
tion (’wiggles’) up to the level of mid-thigh. The power
dial determines the amount of power that drives the
oscillator piston to and fro. The Power control is a 10-
turn locking dial, electrical potentiometer covering the
power range of 0 to 100%. The effect of this control is
to change the displacement of the oscillator piston and
hence to determine the oscillatory pressure ΔP. The
Power setting interacts with the pulmonary artery wedge
(Paw) and the conditions existing within the circuit to
produce the resultant ΔP [33].
On starting HFOV, patients underwent a standardized
slow recruitment maneuver (SRM), which represents the
standard of care for patients receiving HFOV in this
Institution. The SRM is derived from the maneuver
included in the original MOAT Study protocol [34]. The
SRM was performed by a stepwise increase in CDP by
increments of 3 cmH2O every 10 minutes, starting from
the CDP on CMV + 3 to 5 cmH2O, up to 50 cmH2O.
SRM was interrupted if the mean arterial pressure fell
below 55 mmHg or if desaturations (SpO2 <85%) or
arrhythmias occurred. Subsequently, CDP was reduced by
2 cmH2O every 5 minutes. Arterial blood gases were
taken every 10 minutes (every step during the incremen-
tal CDP, phase, and every two steps of the decremental
CDP, phase). The ‘optimal’ CDP was established as the
lowest CDP that achieved the most favorable combina-
tion between the highest PaO2 and/or lowest PaCO2,
while maintaining the FiO2 constant at 1.0.
The protocol for the adjustment of HFOV was pub-
lished previously [25]. A reduction of CDP was initiated
when the FiO2 was ≤0.5. Once CDP ≤20 to 22 cmH2O
was achieved on a FiO2 of 0.4, the patients returned to
CMV. CMV was restarted in the pressure-control mode
with CDP close to the CDP on HFOV, plateau pressures
<28 cmH2O and PEEP adjusted to a tidal volume of
6 mLKg-1 of predicted body weight.
Outcome measures
The primary outcome measures were: improvement in
PaO2/FiO2 and OI and identification of physiological
variables associated with 30-day survival.
To stratify patients we used an empirical score gener-
ated from the available data that was solely designed to
give a pragmatic quantification of disease severity and
not intended to have diagnostic or prognostic value.
The score included PaO2/FiO2, basal PaCO2, respiratory
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system compliance, minute ventilation and mean airway
pressure. This score was used as a dichotomous variable
to separate patients with a more severe index of disease
(score >50th percentile) from those with a less severe
index of disease (score <50th percentile).
Statistical analysis
Distribution of baseline variables was assessed using the
Kolmogorov-Smirnov test. Differences in baseline vari-
ables between survivors and non-survivors were com-
pared using the two-tailed t-test or Mann-Withney U
test for continuous data, and c2 or the Fisher test for
qualitative data. Differences in physiological variables
over time between the two outcome groups were evalu-
ated using repeated-measure analysis of variance
(ANOVA). The Friedman test and Dunn’s post-hoc ana-
lysis was performed for non-normally distributed data.
Multiple regression analysis and analysis of co-variance
(ANCOVA) were used to test the effect of various phy-
siological variables on oxygenation indices. Continuous
outcome variables were corrected for confounding vari-
ables at baseline. Post hoc analyses were performed
using Bonferrroni’s correction. Variables associated with
mortality in an analysis of covariance were entered in a
multivariate logistic backward-likelihood ratio regression
analysis, to identify predictors of mortality at different
end-points. The Hosmer-Lemeshow goodness-of-fit test
was used to test the validity of the model. Receiver-
operating characteristic (ROC) curves were plotted to
determine the best predictor of survival. The value with
the best sensitivity, specificity and positive predictive
value was selected as the cut-off point to predict
survival.
Analyses were performed using SPSS software (version
12; SPSS, Chicago, IL, USA) and MediCalc (Mariakerke,
Belgium) for ROC curve analysis. Two-tailed tests for
significance were used, and a P value less than 0.05 was
considered statistically significant.
Results
We report the results on 102 consecutive ARDS patients
who received HFOV. The median (IQR) duration of
ARDS prior to HFOV was 48 hours (24 to 120 hours).
The median (IQR) duration of CMV prior to HFOV
was 45 hours (9 to 138 hours). Table 1 presents the
baseline patient demographics, physiological variables
and severity scores at study entry. Table 2 summarizes
patients’ outcome and complications from HFOV.
Overall, HFOV was well tolerated with low incidence
of new or worsening pneumothoraces, pneumomediasti-
num or subcutaneous emphysema (2%) and hemody-
namic compromise. Two patients (1.96%) suffered
profound hypotension during HFOV.
Effects of HFOV on gas exchange
During the first 72 hours of HFOV, PaO2/FiO2
improved significantly from baseline only in survivors
(Figure 1a). The earliest time-point at which PaO2/FiO2
was statistically different from baseline in the survivor
group was at three hours of HFOV (P <0.05) (Figure
1a). The improvement in PaO2/FiO2 was not determined
by the level of CDP (Figure 1b) with mean CDP ± SD of
33.9 ± 5.4 cmH2O versus 32.0 ± 7.05 cmH2O (P = 0.08),
respectively, for survivors and non-survivors. The




Age, years 50.8 ± 15.9
Gender, % male 67.6
Actual body weight, Kg 75.7 ± 21.24
APACHEII prior HFOV 24.1 ±8.0
Murray Score 2.98 ± 0.7
Duration ARDS prior HFOV, hours median (IQR) 48 (24 to 120)
Duration CMV prior HFOV, hours median (IQR) 45 (9 to 138)
Gas exchange on CMV pre-HFOV
PaO2, mmHg 74.2 ± 21
PaCO2, mmHg 57.6 ± 18.7
PaO2/FiO2, mmHg 93.8 ± 38.3
SaO2, % 88.6 ± 11.99
OI, cmH2· mmHg
-1 27 ± 13.4
pH 7.26 ± 0.14
Respiratory variables on CMV pre-HFOV
PIP, cmH2O 32.1 ± 5.67
PEEP, cmH2O 12.4 ± 3.7
CDP, cmH2O 21.6 ± 4.97
Compliance 26.4(19.9 to 36.3)
Minute ventilation, L.min-1 10.4 (8.5 to 12.6)
Respiratory rate 20.9 ± 5.1
Tidal volume on CMV, mL 551 (421.7 to 620)
Hemodynamics on CMV pre-HFOV
PAWP, cmH2O 16.8 ± 7.1









Data are presented as absolute number, % or mean ± standard deviation (SD)
unless otherwise indicated. CDP, continuous distending pressure; CMV,
conventional mechanical ventilation; CO, cardiac output; FiO2, fraction of
inspired oxygen; HFOV, high-frequency oscillatory ventilation; PAWP,
pulmonary artery wedge pressure; PEEP, positive end-expiratory pressure; PIP,
peak inspiratory pressure; OI, oxygenation index (OI = (FiO2•CDP•100)/PaO2).
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change in PaO2/FiO2 remained significantly different
(P = 0.03) between the two outcome groups after adjust-
ing for baseline confounding factors such as age, PaO2/
FiO2 and CDP. The independence from CDP during
HFOV was further demonstrated by the divergence of
OI between the two groups and the fact that OI
improved significantly over the first 72 hours only in
survivors (Figure 1c). Analysis of ROC curves identified
an improvement of 38% in PaO2/FiO2 and an improve-
ment of >22% in the OI during the first 72 hours of
HFOV as the criteria with the best positive predictive
values for survival, with respective sensitivities of 93.3%
and 87%, specificities of 78.3% and 78.0% and positive
likelihood ratios of 4.29 and 3.96. Change in PaO2/FiO2
was a better indicator of survival compared with the
change in OI, with an area under the ROC curve of 0.83
(95% CI, 0.71 to 0.92) versus 0.69 (95 % CI 0.55 to 0.8)
(P = 0.039, pair-wise comparison of ROC curves).
Multivariate logistic regression analysis identified the
following four independent predictive factors of mortal-
ity at 30 days: 1) days with ARDS prior to HFOV (OR
1.5, 95%CI 1.08 to 1.92; P = 0.01); 2) improvement in
PaO2/FiO2 in the first 72 hours (OR 0.8, 95 % CI 0.77
to 0.9; P <0.001), 3) age (OR 1.1, 95 % CI 1.02 to 1.14; P
= 0.03); and 4) pre-HFOV pH (OR 0.8, 95 % CI 0.7 to
Table 2 Patient outcomes and complications
Variable
Airleak
Air Leak before HFOV 22/102 (21.6 %)
Persistent air Leak during HFOV 5/22 (22.7 %)
New air leak during HFOV 2/80 (2.5 %)
Co-treatment
(Some patients received more than one co-treatment)
Nitric oxide 21/102 (20.6%)
MARS 1/102 (0.98%)
Steroids 19/102 (18.6%)




Post HFOV 49/102 (48%)
ICU discharge 62/102 (60.8%)
30-day 57/102 (55.9%)
Cause of death at 30-days
Withdrawal of treatment 22/57 (38.6%)
>2 organ failure 20/57 (35.1%)
Cardiac arrhythmia 6/57 (10.5%)
Refractory hypoxia 4/57 (7%)
Sepsis 3/57 (5.3%)
Profound hypotension 2/57 (3.5%)
HFOV, high-frequency oscillatory ventilation; MARS, Molecular Adsorbents
Recirculation System; rhAPC, recombinant human Activated Protein C
(Drotrecogin alfa activated, Xigris).

































































Figure 1 Differences in PaO2/FiO2 ratio, CDP and OI in
survivors (open circles) and non-survivors (filled circles). X-axis
indicates time (hours) on HFOV. Baseline is the time on CMV
immediately preceding the change to HFOV. ‘Last’ is the last
measurement on HFOV prior to returning to CMV. A: Differences
PaO2/FiO2 ratio over time between survivors (open circles) versus
non-survivors (filled circles). B: Trends of change in CDP between
survivors and non-survivors. Data are displayed as mean and error
bars represent SEM at each time-point. The number of patients
(survivors - S; and non-survivors -NS) at different time- points were:
at baseline (S, n = 45; NS, n = 57); 12 hours (S, n = 44; NS, n = 38);
24 hours (S, n = 39; NS, n = 28); 48 hours (S, n = 31; NS, n = 24); 72
hours(S, n = 25; NS, n = 19). * = P <0.01 - comparisons at each
timepoint versus baseline. CDP, continuous distending pressure;
CMV, conventional mechanical ventilation; FiO2, fraction of inspired
oxygen; HFOV, high-frequency oscillatory ventilation; SEM, standard
error of the mean.
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0.9; P = 0.004). The change in PaO2/FiO2 and OI after
three hours of HFOV was the earliest time point to pre-
dict outcome.
There was an interaction between change in PaO2/
FiO2 and the etiology of ARDS, with a greater change in
PaO2/FiO2 for patients with extra-pulmonary ARDS,
independent of baseline PaO2/FiO2, which may reflect
the different degree of lung recruitability.
Effects of HFOV on PaCO2
Survivors had a lower baseline PaCO2 with a median
(IQR) of 47 mmHg (38.6 to 62.2 mmHg) versus 58
mmHg (47.5 to 72.3 mmHg) (P = 0.008) and lower
PaCO2 throughout HFOV treatment (P <0.001) and on
return to CMV (Table 3). Overall, PaCO2 decreased sig-
nificantly throughout the duration of HFOV (P = 0.001,
repeated measure ANOVA) and, at each time-point,
PaCO2 was significantly lower than baseline in both
groups (P <0.001) (Figure 2a).
There was a trend towards greater reduction in PaCO2
in ‘responders’ as defined on the ROC curve by an
increase in PaO2/FiO2 ratio of >38 % compared to ‘non-
responders’ (increase in PaO2/FiO2 ratio of <38 %), with
a median per cent change (IQR) of -17.4 % (-33.4 to
5.48) versus -4.9 % (-19.8 to 11.9) (P = 0.07) (Figure 2b).
Furthermore, patients with a worse empirical disease
severity score showed a more rapid clearance of PaCO2
during the first 12 hours of HFOV (Figure 2c) despite
similar settings of frequency, amplitude and power (Fig-
ure 3). The absolute PaCO2 remained higher in the
more severe group. This result may suggest that patients
with more severe disease have a greater proportion of
recruitable lung and an increase in alveolar ventilation
following HFOV. Overall, patients with lower respiratory
system compliance had a trend towards a greater change
in PaCO2 post-SRM (-20.5% versus -2.4 %; P = 0.08),
and there was a correlation between change in PaCO2
post-SRM and change in compliance post-HFOV (r2 =
0.6; P = 0.04).
Discussion
This study aimed to identify potential predictors of sur-
vival in patients with severe ARDS who received HFOV
after failing lung-protective CMV. The key results of
our study are that: 1) an early improvement in PaO2/
FiO2 ratio is a predictor of survival at 30 days; 2)
patients with more severe disease and lower respiratory
system compliance pre-HFOV show greater CO2 clear-
ance; and 3) if there is no improvement in gas exchange
within three hours, patients can be considered to have









Mean SD Mean SD P
value
Demographics
Age, years 45.7 16.2 54.9 14.6 0.003
Weight, Kg 75.8 22.7 75.6 20.2 ns
APACHE II (prior to HFOV) 22.9 6.52 24.98 8.96 ns
Murray Score 3.0 0.62 2.9 0.77 ns
Duration ARDS prior to HFOV,
days
2.9 3.6 4.5 4.7 0.015
Duration CMV prior to HFOV,
hours
88.9 131.9 90.4 105.9 ns
Gas exchange indices
PaO2/ FiO2 prior to HFOV,
mmHg
96.8 38.8 90.8 38.3 ns
PaO2/ FiO2 return to CMV,
mmHg
211.5 96.0 129.0 70.5 0.001
Δ PaO2 / FiO2 111.0 89.3 26.7 63.0 <0.01
PaCO2 prior to HFOV, mmHg 54.0 20.8 60.8 17.0 ns
PaCO2 return to CMV, mmHg 50.3 17.3 81.8 97.4 0.049
OI prior HFOV, cmH2O·
mmHg-1
26.1 13.4 27.6 13.4 ns
OI return to CMV, cmH2O·
mmHg-1
10.1 6.6 21.8 19.1 0.01
Max PaCO2, mmHg 55.5 10.6 66.7 18.8 <0.01
Min PaCO2, mmHg 36.0 6.7 47.9 16.0 <0.01
pH prior to HFOV 7.3 0.14 7.23 0.12 <0.01
pH return to CMV 7.4 0.1 7.27 0.1 <0.01
Hemodynamic indices
MAP prior to HFOV, mmHg 76.3 15.4 75.1 12.9 ns
MAP return to CMV, mmHg 82.9 14.6 77.0 20.9 ns
CO prior to HFOV, L · min-1 6.1 2.0 5.8 1.5 ns
CO return to CMV, L ·min-1 5.9 1.3 6.1 0.5 ns
Ventilator Indices ns
Vt prior to HFOV, mL ·Kg-1 7.4 2.4 6.9 2.2 ns
Vt return to CMV, mL ·Kg-1 6.9 2.1 6.8 1.9 ns
PIP prior to HFOV, cmH2O 31.8 6.2 32.3 5.2 ns
PIP return to CMV, cmH2O 28.5 5.2 30.3 5.98 ns
PEEP prior to HFOV, cmH2O 12.9 4.0 12.1 3.4 ns
PEEP return to CMV, cmH2O 10.5 2.7 10.8 3.3 ns
CDP prior to HFOV, cmH2O 21.8 5.7 21.4 4.3 ns
CDP return to CMV, cmH2O 17.5 4.5 20.7 5.9 0.02
Δ CDP, cmH2O -3.9 6.5 -0.57 4.6 0.03
CDP, continuous distending pressure; CMV, conventional mechanical
ventilation; CO, cardiac output; FiO2, fraction of inspired oxygen; HFOV, high-
frequency oscillatory ventilation; OI,Oxygenation Index (OI = (FiO2•CDP•100)/
PaO2); PAWP, pulmonary artery wedge pressure; PEEP, positive end-expiratory
pressure; PIP, peak inspiratory pressure; Vt, tidal volume; = change post-HFOV
to pre-HFOV.
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failed HFOV and perhaps should be considered for
alternative treatment (for example, extracorporeal
support).
Despite theoretical beneficial effects on minimizing
lung injury and improving gas exchange, HFOV is not
widely utilized because of the lack of evidence support-
ing a clear survival benefit over CMV [25,26,34].
Furthermore, available clinical trials do not help the
clinician decide when to consider HFOV and, impor-
tantly, how long HFOV should be continued to enhance
patient survival. Our study has a similar scope to the
series reported by Adhikari et al. [23]; however, there
are important methodological differences in the HFOV
protocols and the type of recruitment maneuver (that is,
a slow stepwise maneuver in our study versus a sus-
tained inflation in Adhikari et al.) used in the two stu-
dies. Furthermore, recruitment maneuvers were
performed in all patients in our case series, whereas in
the study by Adhikari et al only 49.5% of the patients
received a recruitment maneuver. The rationale of the
stepwise recruitment we used in this study was similar
to the stepwise recruitment used in neonates [35], in
that it allowed for setting of the optimal CDP but it dif-
fered in two aspects. First, we used a fixed FiO2 of 1.0
and response to the recruitment was assessed as changes
in PaO2. Second, in order to allow time for equilibration
of PaO2 [36] and to minimize hemodynamic instability,
our protocol required longer times between changes in
CDP (ten minutes during the incremental phase and
five minutes during the decremental phase) compared
to the recruitment used in neonates [35]. It is possible
that the slower and early recruitment, as performed in
this study, can explain the early identification of respon-
ders to HFOV.
Although our study is not a randomized comparative
study, we believe it identifies clinically important predic-
tors of clinical outcome within the first few hours of initia-
tion of HFOV, possibly in response to the initial SRM. Our
study population included, as might be expected for a res-
cue study, patients with more severe ARDS than in the
MOAT trial where patients received HFOV as a primary
ventilation mode [26] and similar to that of the EMOAT
trial [25] and the recent case series[23].
In contrast to other published reports [17,18], in our
study gas exchange variables (PaO2/FiO2, and OI)
improved significantly only in survivors, and change in
PaO2/FiO2 remained significantly different between the
two outcome groups after adjusting for baseline con-
founding factors. Although the CDP on HFOV was
higher than the CDP on CMV, there was no difference
in CDP between survivors and non-survivors. Despite
similar levels of CDP, the response to HFOV within the
first three hours could identify patients with a favorable
outcome based on PaO2/FiO2 and OI.
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Figure 2 Changes in PaCO2 based on survival status, response
to HFOV and disease severity. A: Differences in PaCO2 in survivors
(open circles) and non-survivors (filled circles) over 72 hours of
HFOV. X-axis indicates time (hours) on HFOV. Time 0 is the time on
CMV immediately preceding the change to HFOV. ‘Last’ is the last
measurement on HFOV prior to returning to CMV. There was no
difference in the trend of change in PaCO2 between the two
outcome groups. Data are displayed as mean and error bars
represent SEM at each time-point. B: Patients were subdivided into
two groups (responders and non-responders) based on the analysis
of the ROC curve. They were considered responders if their PaO2/
FiO2 ratio improved >38% from baseline. Responders show a trend
towards better CO2 clearance (P = 0.07). Data are displayed as mean
and error bars represent SEM. C: Patients were subdivided into two
groups based on disease severity. Patients with more severe disease
(open circles) have a greater clearance in PaCO2. The number of
patients (Survivors - S; and non-survivors -NS) at different time-
points after initiating HFOV were: at baseline (S, n = 45; NS, n = 57);
12 hours (S, n = 44; NS, n = 38); 24 hours (S, n = 39; NS, n = 28); 48
hours (S, n = 31; NS, n = 24); 72 hours (S, n = 25; NS, n = 19). CMV,
conventional mechanical ventilation; FiO2, fraction of inspired
oxygen; HFOV, high-frequency oscillatory ventilation; PaCO2, partial
pressure of carbon dioxide in arterial blood; ROC, receiver-operating
curve; SEM, standard error of the mean.
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Figure 3 Differences in HFOV settings over time between survivors and non-survivors. A: Differences in Delta pressure (ΔP) in survivors
(open circles) and non-survivors (filled circles) over 72 hours of HFOV. There was a significant difference in the ΔP between the two outcome
groups. Data are displayed as mean and error bars represent SD at each time-point. * = P <0.01 between the two groups. B: Differences in
frequency in survivors (open circles) and non-survivors (filled circles) over 72 hours of HFOV. There was a significant difference in the frequency
between the two outcome groups at 24 hours. Data are displayed as mean and error bars represent SD at each time-point. * = P <0.01 between
the two groups. HFOV, high-frequency oscillatory ventilation.
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An important factor for the response to HFOV may
be played by the proportion of patients with pulmonary
versus extra-pulmonary ARDS. Indeed, in this study we
show that the largest change in PaO2/FiO2 post HFOV
was seen for extra-pulmonary ARDS whereas little dif-
ference in PaO2/FiO2 was seen in pulmonary ARDS.
This is consistent with the findings reported by Pachl et
al. that show that oxygenation and recruitment during
HFOV are more pronounced in patients with extra-pul-
monary ARDS [37]. However, Pachl et al. studied
changes in oxygenation under normocapnic conditions;
therefore, no data on the different behavior of PaCO2 in
the two types of ARDS are available for comparison
with our data. The other important finding of our study
is the effect of HFOV on PaCO2. In our study, in con-
trast to other reports [19,26], the PaCO2 decreased sig-
nificantly throughout the duration of HFOV in parallel
to an increase in PaO2/FiO2 despite similar settings of
frequency, power and amplitude. We found that in sur-
vivors there was both an increase in PaO2/FiO2 and a
decrease in PaCO2. In addition, patients who had at
least a 38% increase in their PaO2//FiO2 (as identified by
the ROC curve), also showed greater reductions in
PaCO2 allowing for a reduction in delta pressure.
Patients with a greater disease severity (higher PaCO2,
lower compliance and worse gas exchange), showed a
higher rate of clearance in PaCO2 during the first six
hours of HFOV. These changes in physiological vari-
ables have been described in patients with severe ARDS
and higher potential for lung recruitment [38].
The increase in intra-thoracic pressure generated dur-
ing a SRM could have caused a reduction in cardiac
output and pulmonary blood flow, leading to a decrease
in venous admixture and to an apparent improvement
in PaO2/FiO2 in the absence of true alveolar recruitment
[39,40]. However, this mechanism seems less likely as an
explanation for the changes seen in our study, as the
cardiac output and oxygen delivery were unchanged fol-
lowing the SRM, and therefore the combined improve-
ment in PaO2/FiO2 and PaCO2 leads us to speculate
that HFOV facilitated lung recruitment in a manner
similar to that described for patients responding to
prone positioning [41].
The 30-day mortality in this study was 56%, compar-
able to the mortality rate reported in other uncontrolled
studies (61.7% [23,42], 66% [18], 53% [17]) but higher
than the studies using HFOV as primary intervention
(43% [25] and 37% [26]) and studies of trauma patients
[16]. Multivariate analysis shows that changes in PaO2/
FiO2, age, days with ARDS prior to HFOV and baseline
pH are independent predictive factors of mortality. Lung
injury is positively associated with duration of mechanical
ventilation in both animal and human studies: increased
lung injury is associated with reduced likelihood of pul-
monary recruitment
Conclusions
In conclusion, this study shows that HFOV is effective
in improving oxygenation in some adults with ARDS,
particularly when instituted early. This study also shows
that changes in PaO2/FiO2 are sensitive criteria to pre-
dict survival and the change in PaCO2 may identify
patients with a greater proportion of recruitable lung
more likely to benefit from HFOV. Patients who do not
show improvement in PaO2/FiO2 ratio and oxygenation
index within six hours on commencing HFOV should
be considered for extracorporeal support. These data are
of potential value in aiding decision making.
Further randomized controlled trials powered to
detect a difference in survival between HFOV strategies
are expected. Interpretation of these comparisons will
also need to take into consideration the number, the
duration, and the type of recruitment maneuvers carried
out during HFOV and CMV (for example, slow stepwise
RMs, as employed in this study versus traditional RMs,
with continuous positive airway pressure (CPAP) of 40
cmH2O for 40 seconds). The identification of patients
likely to benefit from HFOV and the identification of
physiological variables associated with the potential for
lung recruitment will prove essential to ensure the best
use of HFOV in adults with ARDS.
Key messages
• Changes in PaO2/FiO2 early during HFOV are sensi-
tive criteria to predict survival.
• Patients who do not show improvement in the
PaO2/FiO2 ratio and OI within three hours should be
considered for alternative treatment (for example, extra-
corporeal support).
• The identification of patients likely to benefit from
HFOV and the identification of physiological variables
associated with the potential for lung recruitment will
prove essential to ensure the best use of HFOV in adults
with ARDS.
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